HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany
HER2 testing in metastatic gastric or gastroesophageal junction cancer (mGC/mGEJC) is standard practice. Variations in HER2-positivity rates suggest factors affecting test quality; however, the influence of patient-, tumor-, and laboratory-related factors on HER2-positivity rates remains unknown. Th...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2 March 2019
|
| In: |
Virchows Archiv
Year: 2019, Jahrgang: 474, Heft: 5, Pages: 551-560 |
| ISSN: | 1432-2307 |
| DOI: | 10.1007/s00428-019-02541-9 |
| Online-Zugang: | Verlag, Pay-per-use, Volltext: https://doi.org/10.1007/s00428-019-02541-9
|
| Verfasserangaben: | Gustavo Baretton, Hans H. Kreipe, Peter Schirmacher, Timo Gaiser, Ralf Hofheinz, Karl-Heinz Berghäuser, Winfried Koch, Claudia Künzel, Stefanie Morris, Josef Rüschoff on behalf of the Nicht-interventionelle Untersuchung (NIU) HER2 Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1677950196 | ||
| 003 | DE-627 | ||
| 005 | 20230428021909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190930s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00428-019-02541-9 |2 doi | |
| 035 | |a (DE-627)1677950196 | ||
| 035 | |a (DE-599)KXP1677950196 | ||
| 035 | |a (OCoLC)1341244775 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Baretton, Gustavo Bruno |e VerfasserIn |0 (DE-588)1022411691 |0 (DE-627)716964848 |0 (DE-576)365286346 |4 aut | |
| 245 | 1 | 0 | |a HER2 testing in gastric cancer diagnosis |b insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany |c Gustavo Baretton, Hans H. Kreipe, Peter Schirmacher, Timo Gaiser, Ralf Hofheinz, Karl-Heinz Berghäuser, Winfried Koch, Claudia Künzel, Stefanie Morris, Josef Rüschoff on behalf of the Nicht-interventionelle Untersuchung (NIU) HER2 Study Group |
| 264 | 1 | |c 2 March 2019 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.09.2019 | ||
| 520 | |a HER2 testing in metastatic gastric or gastroesophageal junction cancer (mGC/mGEJC) is standard practice. Variations in HER2-positivity rates suggest factors affecting test quality; however, the influence of patient-, tumor-, and laboratory-related factors on HER2-positivity rates remains unknown. This observational, prospective study collected routine HER2 testing data from 50 pathology centers in Germany (January 2013-December 2015). For each sample, HER2 status, primary tumor location, method of sample retrieval, and other patient- and tumor-related parameters were recorded. A model for predicting the probability of HER2-positivity was developed using stepwise multiple logistic regression to identify influencing factors. Documented positivity rates and corresponding predicted HER2-positivity probabilities were compared to identify institutes with deviations in HER2-positivity. Data from 2761 mGC/mGEJC routine diagnostic specimens included 2033 with HER2 test results (1554 mGC, 479 mGEJC); overall HER2-positivity rates across centers were 19.8% and 30.5%, respectively. HER2-positivity correlated most with Lauren classification, then HER2 testing rate, primary tumor location, sample type, and testing method (all p < 0.05). Three institutes had model-predicted HER2-positivity rates outside the 95% confidence interval of their documented rate, which could not be explained by sample and center characteristics. Results demonstrated the high quality of routine HER2 testing in the mGC/mGEJC cohort analyzed. This is the first study investigating parameters impacting on HER2-positivity rates in mGC/mGEJC in routine practice and suggests that assessment of HER2 testing quality should consider primary tumor location, testing method and rate, and tumor characteristics. Accurate identification of patients with HER2-positive mGC/mGEJC is essential for appropriate use of HER2-targeted therapies. | ||
| 650 | 4 | |a Gastric cancer | |
| 650 | 4 | |a Gastroesophageal junction cancer | |
| 650 | 4 | |a HER2 testing | |
| 650 | 4 | |a HER2-positivity | |
| 650 | 4 | |a Statistical model | |
| 700 | 1 | |a Schirmacher, Peter |d 1961- |e VerfasserIn |0 (DE-588)1020440112 |0 (DE-627)691221197 |0 (DE-576)360427448 |4 aut | |
| 700 | 1 | |a Gaiser, Timo |d 1975- |e VerfasserIn |0 (DE-588)1030402280 |0 (DE-627)735221685 |0 (DE-576)378226533 |4 aut | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virchows Archiv |d Berlin : Springer, 1847 |g 474(2019), 5, Seite 551-560 |h Online-Ressource |w (DE-627)254910645 |w (DE-600)1463276-7 |w (DE-576)074754416 |x 1432-2307 |7 nnas |a HER2 testing in gastric cancer diagnosis insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany |
| 773 | 1 | 8 | |g volume:474 |g year:2019 |g number:5 |g pages:551-560 |g extent:10 |a HER2 testing in gastric cancer diagnosis insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00428-019-02541-9 |x Verlag |x Resolving-System |z Pay-per-use |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190930 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 63300 |e 60000PH121917517 |e 63300PH121917517 |k 0/60000/ |k 1/60000/63300/ |p 5 | ||
| 998 | |g 1030402280 |a Gaiser, Timo |m 1030402280:Gaiser, Timo |d 60000 |d 63400 |e 60000PG1030402280 |e 63400PG1030402280 |k 0/60000/ |k 1/60000/63400/ |p 4 | ||
| 998 | |g 1020440112 |a Schirmacher, Peter |m 1020440112:Schirmacher, Peter |d 910000 |d 912000 |e 910000PS1020440112 |e 912000PS1020440112 |k 0/910000/ |k 1/910000/912000/ |p 3 | ||
| 999 | |a KXP-PPN1677950196 |e 3519131420 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"HER2 testing in gastric cancer diagnosis","title":"HER2 testing in gastric cancer diagnosis","subtitle":"insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany"}],"person":[{"display":"Baretton, Gustavo Bruno","given":"Gustavo Bruno","role":"aut","family":"Baretton"},{"family":"Schirmacher","role":"aut","given":"Peter","display":"Schirmacher, Peter"},{"family":"Gaiser","display":"Gaiser, Timo","given":"Timo","role":"aut"},{"family":"Hofheinz","display":"Hofheinz, Ralf-Dieter","given":"Ralf-Dieter","role":"aut"}],"name":{"displayForm":["Gustavo Baretton, Hans H. Kreipe, Peter Schirmacher, Timo Gaiser, Ralf Hofheinz, Karl-Heinz Berghäuser, Winfried Koch, Claudia Künzel, Stefanie Morris, Josef Rüschoff on behalf of the Nicht-interventionelle Untersuchung (NIU) HER2 Study Group"]},"relHost":[{"pubHistory":["1.1847 -"],"title":[{"title_sort":"Virchows Archiv","subtitle":"official journal of the European Society of Pathology","title":"Virchows Archiv"}],"language":["eng"],"part":{"year":"2019","text":"474(2019), 5, Seite 551-560","volume":"474","extent":"10","pages":"551-560","issue":"5"},"origin":[{"dateIssuedKey":"1847","dateIssuedDisp":"1847-","publisher":"Springer","publisherPlace":"Berlin ; Heidelberg"}],"recId":"254910645","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"Archiv für pathologische Anatomie und Physiologie und für klinische Medicin"},{"title":"Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin"},{"title":"Virchows Archiv / A"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"HER2 testing in gastric cancer diagnosis insights on variables influencing HER2-positivity from a large, multicenter, observational study in GermanyVirchows Archiv","id":{"eki":["254910645"],"zdb":["1463276-7"],"issn":["1432-2307"]},"note":["Gesehen am 06.12.05"],"corporate":[{"display":"European Society of Pathology","role":"isb"}]}],"note":["Gesehen am 30.09.2019"],"id":{"doi":["10.1007/s00428-019-02541-9"],"eki":["1677950196"]},"physDesc":[{"extent":"10 S."}],"origin":[{"dateIssuedDisp":"2 March 2019","dateIssuedKey":"2019"}],"recId":"1677950196","type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a BARETTONGUHER2TESTIN2201 | ||